Nuclear receptor coregulators: Promising therapeutic targets for the treatment of prostate cancer

Hannelore V. Heemers, Donald J. Tindall

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

The concept that androgens exert control over the prostate and prostate disease dates back to the eighteenth century, when the first observations of seasonal variations in the size of the prostate gland were observed in animals. Since then, a direct link between testis-derived androgens and prostate growth was established, leading to the seminal study of Charles Huggins who demonstrated that surgical or medical castration is able to inhibit the growth of metastatic and advanced prostate cancer (CaP). Today, more than six decades after Huggins' original groundbreaking report, so-called androgen deprivation therapies are still the preferred treatment option for CaP patients who do not benefit from surgery or radiation therapy. While such treatment regimes initially result in a clinical favorable response and an overall decrease in tumor burden in a majority of patients, disease regression is not complete, and androgen deprivation is therefore not curative. Recent findings of physiologically relevant tissue levels of androgens in castration-recurrent prostate cancer (CRPC) have led to a paradigm shift that CaP, which recurs following androgen deprivation therapy, is not androgen-independent and has rekindled research into alternative means of blocking androgen action as a therapeutic option during prostate cancer progression. Here, we explore the possibility of targeting coregulator proteins, which are critical determinants for androgenic responses, as an indirect means of blocking androgen action in CaP cells.

Original languageEnglish (US)
Title of host publicationDrug Management of Prostate Cancer
PublisherSpringer New York
Pages41-51
Number of pages11
ISBN (Print)9781603278317
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Cytoplasmic and Nuclear Receptors
Androgens
Prostatic Neoplasms
Prostate
Therapeutics
Castration
Protein Transport
Growth
Tumor Burden
Testis
Radiotherapy
Research

Keywords

  • Androgen
  • Androgen receptor
  • Cell proliferation
  • Coactivator
  • Corepressor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Heemers, H. V., & Tindall, D. J. (2010). Nuclear receptor coregulators: Promising therapeutic targets for the treatment of prostate cancer. In Drug Management of Prostate Cancer (pp. 41-51). Springer New York. https://doi.org/10.1007/978-1-60327-829-4_3

Nuclear receptor coregulators : Promising therapeutic targets for the treatment of prostate cancer. / Heemers, Hannelore V.; Tindall, Donald J.

Drug Management of Prostate Cancer. Springer New York, 2010. p. 41-51.

Research output: Chapter in Book/Report/Conference proceedingChapter

Heemers, HV & Tindall, DJ 2010, Nuclear receptor coregulators: Promising therapeutic targets for the treatment of prostate cancer. in Drug Management of Prostate Cancer. Springer New York, pp. 41-51. https://doi.org/10.1007/978-1-60327-829-4_3
Heemers HV, Tindall DJ. Nuclear receptor coregulators: Promising therapeutic targets for the treatment of prostate cancer. In Drug Management of Prostate Cancer. Springer New York. 2010. p. 41-51 https://doi.org/10.1007/978-1-60327-829-4_3
Heemers, Hannelore V. ; Tindall, Donald J. / Nuclear receptor coregulators : Promising therapeutic targets for the treatment of prostate cancer. Drug Management of Prostate Cancer. Springer New York, 2010. pp. 41-51
@inbook{b95eea96a6014ef89502827d088cd726,
title = "Nuclear receptor coregulators: Promising therapeutic targets for the treatment of prostate cancer",
abstract = "The concept that androgens exert control over the prostate and prostate disease dates back to the eighteenth century, when the first observations of seasonal variations in the size of the prostate gland were observed in animals. Since then, a direct link between testis-derived androgens and prostate growth was established, leading to the seminal study of Charles Huggins who demonstrated that surgical or medical castration is able to inhibit the growth of metastatic and advanced prostate cancer (CaP). Today, more than six decades after Huggins' original groundbreaking report, so-called androgen deprivation therapies are still the preferred treatment option for CaP patients who do not benefit from surgery or radiation therapy. While such treatment regimes initially result in a clinical favorable response and an overall decrease in tumor burden in a majority of patients, disease regression is not complete, and androgen deprivation is therefore not curative. Recent findings of physiologically relevant tissue levels of androgens in castration-recurrent prostate cancer (CRPC) have led to a paradigm shift that CaP, which recurs following androgen deprivation therapy, is not androgen-independent and has rekindled research into alternative means of blocking androgen action as a therapeutic option during prostate cancer progression. Here, we explore the possibility of targeting coregulator proteins, which are critical determinants for androgenic responses, as an indirect means of blocking androgen action in CaP cells.",
keywords = "Androgen, Androgen receptor, Cell proliferation, Coactivator, Corepressor",
author = "Heemers, {Hannelore V.} and Tindall, {Donald J.}",
year = "2010",
doi = "10.1007/978-1-60327-829-4_3",
language = "English (US)",
isbn = "9781603278317",
pages = "41--51",
booktitle = "Drug Management of Prostate Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Nuclear receptor coregulators

T2 - Promising therapeutic targets for the treatment of prostate cancer

AU - Heemers, Hannelore V.

AU - Tindall, Donald J.

PY - 2010

Y1 - 2010

N2 - The concept that androgens exert control over the prostate and prostate disease dates back to the eighteenth century, when the first observations of seasonal variations in the size of the prostate gland were observed in animals. Since then, a direct link between testis-derived androgens and prostate growth was established, leading to the seminal study of Charles Huggins who demonstrated that surgical or medical castration is able to inhibit the growth of metastatic and advanced prostate cancer (CaP). Today, more than six decades after Huggins' original groundbreaking report, so-called androgen deprivation therapies are still the preferred treatment option for CaP patients who do not benefit from surgery or radiation therapy. While such treatment regimes initially result in a clinical favorable response and an overall decrease in tumor burden in a majority of patients, disease regression is not complete, and androgen deprivation is therefore not curative. Recent findings of physiologically relevant tissue levels of androgens in castration-recurrent prostate cancer (CRPC) have led to a paradigm shift that CaP, which recurs following androgen deprivation therapy, is not androgen-independent and has rekindled research into alternative means of blocking androgen action as a therapeutic option during prostate cancer progression. Here, we explore the possibility of targeting coregulator proteins, which are critical determinants for androgenic responses, as an indirect means of blocking androgen action in CaP cells.

AB - The concept that androgens exert control over the prostate and prostate disease dates back to the eighteenth century, when the first observations of seasonal variations in the size of the prostate gland were observed in animals. Since then, a direct link between testis-derived androgens and prostate growth was established, leading to the seminal study of Charles Huggins who demonstrated that surgical or medical castration is able to inhibit the growth of metastatic and advanced prostate cancer (CaP). Today, more than six decades after Huggins' original groundbreaking report, so-called androgen deprivation therapies are still the preferred treatment option for CaP patients who do not benefit from surgery or radiation therapy. While such treatment regimes initially result in a clinical favorable response and an overall decrease in tumor burden in a majority of patients, disease regression is not complete, and androgen deprivation is therefore not curative. Recent findings of physiologically relevant tissue levels of androgens in castration-recurrent prostate cancer (CRPC) have led to a paradigm shift that CaP, which recurs following androgen deprivation therapy, is not androgen-independent and has rekindled research into alternative means of blocking androgen action as a therapeutic option during prostate cancer progression. Here, we explore the possibility of targeting coregulator proteins, which are critical determinants for androgenic responses, as an indirect means of blocking androgen action in CaP cells.

KW - Androgen

KW - Androgen receptor

KW - Cell proliferation

KW - Coactivator

KW - Corepressor

UR - http://www.scopus.com/inward/record.url?scp=77952893011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952893011&partnerID=8YFLogxK

U2 - 10.1007/978-1-60327-829-4_3

DO - 10.1007/978-1-60327-829-4_3

M3 - Chapter

AN - SCOPUS:77952893011

SN - 9781603278317

SP - 41

EP - 51

BT - Drug Management of Prostate Cancer

PB - Springer New York

ER -